Patients & Families

In these challenging times of the COVID-19 pandemic, we offer our support and gratitude to you, the patient community. We can only imagine how difficult it must be to live with a chronic illness at the same time. For our patients, we remain steadfast and committed to doing what we can to limit the impact of this pandemic. Regarding our clinical trials, we continue to provide the ability to enroll, access to study drug and explore options to address further impacts of quarantines and stay at home orders.

We will continue to find new ways to help and engage with you as we work together to improve your quality of life.

We are working tirelessly to bring transformative therapies to patients.

Our mission is to make best-in-class medicines to address unmet medical needs by changing the way small molecule drugs are designed. We are a late-stage biopharmaceutical company developing next-generation oral therapies — immuno-modulators — that have the potential to transform the treatment of underserved patients who have immune-mediated diseases. Our clinical trials are designed to determine if our product candidates are safe and efficacious. We also look at additional aspects of care, such as improvements in quality of life for people with chronic illnesses.

Why Participate in a Clinical Trial?

By participating in a clinical trial, patients receive access to the newest treatments available while contributing to a better understanding of specific diseases and how best to treat them. Clinical trials are primarily conducted to help future patients by providing valuable information about the risks and benefits of investigational drug candidates. If you would like to learn more about the clinical trial process, you can access this information through the U.S. Food Administration website.

If you are considering participating in a clinical trial, you should speak with your doctor. If you are interested in learning more about our trials, diseases that we are pursuing, patient resources or gaining access to our product candidates, please visit our clinical studies overview page. There are helpful links below. You will also find more detailed information about our PEGASUS study, an ongoing Phase 3 clinical trial in pemphigus designed to evaluate rilzabrutinib (formerly known as PRN1008) versus placebo. Further, you can learn about accessing our investigational therapies by visiting our access policy page.

Note: All of Principia’s drug candidates are investigational only and not approved for sale.

You can also search for other clinical trials in the United States at ClinicalTrials.gov or in the European Union at the EU Clinical Trials Register.

Ongoing Clinical Studies

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website